Conference Proceedings
Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study
Alice McDonald, Elizabeth Thomas, Scott Daigle, Franck Morschhauser, Gilles Salles, Vincent Ribrag, Pamela McKay, Herve Tilly, Anna Schmitt, Connie Lee Batlevi, Christophe Fruchart, Peter Johnson, Michael Dickinson, Stephen Opat, Wojciech Jurczak, Guillaume Cartron, Thierry Lamy, Pier Luigi Zinzani, Sarit Assouline, John Radford Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract Introduction: B-cell malignancies may depend on the histone methyltransferase EZH2 to perpetuate a less differentiated state, with activating mutations of EZH2 being potential oncogenic drivers. Tazemetostat, a potent, selective EZH2 inhibitor, is in phase 2 clinical development in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Objective responses were observed in patients (pts) with EZH2 mutant or wild type tumors in the phase 1 part of the phase 1/2 study. The ongoing phase 2 study is enrolling pts with mutant or wild type EZH2 having R/R diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) to determine efficacy and safety. The primary endpoin..
View full abstract